Illumina (NASDAQ:ILMN) Shares Cross Below Fifty Day Moving Average Following Analyst Downgrade

Illumina, Inc. (NASDAQ:ILMN) shares crossed below its 50 day moving average during trading on Friday after JPMorgan Chase & Co. lowered their price target on the stock from $320.00 to $300.00. The stock has a 50 day moving average of $249.30 and traded as low as $231.18. JPMorgan Chase & Co. currently has an overweight rating on the stock. Illumina shares last traded at $235.99, with a volume of 5,389,541 shares traded.

A number of other research firms have also weighed in on ILMN. Weiss Ratings reissued a “hold (c)” rating on shares of Illumina in a research note on Monday, August 31st. Piper Sandler boosted their target price on Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, September 28th. Guggenheim upped their price target on Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Evercore reaffirmed an “underperform” rating on shares of Illumina in a report on Friday. Finally, Argus lifted their price objective on Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a research report on Thursday, September 3rd. Nine research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $238.53.

Insider Activity at Illumina

In other Illumina news, Director Keith A. Meister sold 119,501 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the sale, the director owned 770,350 shares of the company’s stock, valued at $168,244,440. This trade represents a 13.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Christensen Wedel sold 1,033 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 2,061,235 shares of company stock worth $436,356,102. Corporate insiders own 2.90% of the company’s stock.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Hedge Funds Weigh In On Illumina

A number of hedge funds have recently modified their holdings of ILMN. Rakuten Investment Management Inc. purchased a new stake in Illumina in the third quarter valued at $7,311,000. Provenance Wealth Advisors LLC purchased a new position in shares of Illumina during the third quarter worth about $74,000. IPG Investment Advisors LLC purchased a new position in shares of Illumina during the third quarter worth about $2,379,000. Signature Equity Partners LLC increased its position in shares of Illumina by 246.5% during the third quarter. Signature Equity Partners LLC now owns 149 shares of the life sciences company’s stock worth $41,000 after purchasing an additional 106 shares in the last quarter. Finally, XML Financial LLC acquired a new stake in shares of Illumina during the third quarter worth about $320,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $35.63 billion, a PE ratio of 40.62, a P/E/G ratio of 4.11 and a beta of 1.41. The company has a fifty day moving average price of $249.30 and a two-hundred day moving average price of $176.18.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. The firm had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.15 billion. Illumina had a return on equity of 29.41% and a net margin of 19.72%. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.34 EPS. Sell-side analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current year.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.